melanotan 1 dosage: Frequently asked questions

Discard the vial and reconstitute a fresh dose. Lyophilized peptides tolerate ambient temperature before reconstitution, but once dissolved in bacteriostatic water, MT-1's tertiary protein structure denatures above 8°C within 8–12 hours. The solution may appear visually unchanged. Clear and colorless. But the peptide is pharmacologically inactive. Injecting denatured MT-1 produces no melanogenesis and wastes the dose entirely.

Reduce the dose by 50% for 3–5 days, then re-escalate slowly. Nausea from MT-1 results from off-target MC4R activation in the hypothalamus, which regulates appetite and emesis pathways. Starting at 0.25mg minimizes this risk, but 15–20% of subjects still experience mild nausea during loading phase. Taking the injection with food and avoiding fatty meals for 2 hours post-dose reduces symptom severity. If nausea persists beyond 48 hours at reduced dose, discontinue the protocol. MT-1 may not be suitable for that subject.

Increase to 0.75mg daily and verify UV co-exposure is occurring. MT-1 cannot produce visible pigmentation without UV stimulus to activate tyrosinase. The peptide primes melanocytes but requires oxidative stress to catalyze melanin polymerization. If UV exposure is confirmed and tanning remains absent at 0.75mg after another 7 days, escalate to 1.0mg daily as the final step. Subjects who show no response at 1.0mg likely have MC1R polymorphisms (common in individuals with red hair and Fitzpatrick Type I skin) that prevent receptor activation regardless of dose.

Skip the next scheduled dose and resume at your standard dose 24 hours later. MT-1's 33-minute serum half-life means the acute overdose clears rapidly, but the melanocortin receptors remain activated for 12–18 hours post-injection. Doubling up within this window compounds receptor overstimulation. Monitor for nausea, facial flushing, and spontaneous erections (males); if these persist beyond 6 hours or become severe, discontinue the protocol and allow 48-hour washout before restarting at 0.25mg.

Reduce dose to 0.5mg and inject immediately after a small meal containing 10–15g protein and complex carbohydrates. The nausea results from α-MSH cross-reactivity with MC4R receptors in the hypothalamus, which regulate appetite and satiety. Food blunts this effect by 40–50% without reducing melanogenic potency. If nausea persists beyond day 5 at 0.5mg, discontinue. You're likely a poor MC4R metaboliser and won't tolerate therapeutic MT-1 doses.

Lack of visible pigmentation by day five suggests either insufficient dose (common in individuals with MC1R loss-of-function variants) or absence of sub-erythemal UV exposure during loading. Melanotan-1 primes melanocytes for pigmentation, but UV exposure is required to activate melanin deposition into keratinocytes. The peptide alone won't darken skin without concurrent UV stimulus. If you've been indoors throughout the loading phase, expose skin to 10–15 minutes of midday sun (enough to produce mild pinkness but not burning) on day six and reassess pigmentation 48 hours later. If pigmentation remains absent despite UV exposure, consider dose escalation to 0.18–0.20mg/kg, but monitor closely for GI side effects.

Administer the second implant as soon as logistically possible and extend sun-protection behaviours (clothing, shade-seeking) until melanogenesis fully establishes. Afamelanotide's melanogenic effect persists for 2–4 weeks after plasma concentrations drop below detectable limits because melanin already synthesised remains in keratinocytes until those cells desquamate. Missing the second implant by 1–2 weeks reduces photoprotection slightly but doesn't eliminate it. Missing by 4+ weeks may leave patients vulnerable during peak summer UV.

Uneven fading typically indicates inconsistent injection timing during the protocol. Melanocytes that received peak peptide exposure during morning administration retain pigmentation longer than those activated at suboptimal times. The fade is gradual and natural, taking 4–6 weeks to return to baseline. UV exposure during this period extends pigmentation because MT-1-induced melanin remains photoprotective. There's no 'crash'. Eumelanin degrades through normal keratinocyte turnover.

Extend the protocol to 14 days before adjusting dose. Some Fitzpatrick I users require 12–14 days for visible melanin deposition, especially if injecting outside the morning circadian window. If still no change after 14 days, verify peptide integrity: was it stored at −20°C before reconstitution? Was bacteriostatic water used? Cloudy solution or room-temperature storage during shipping both indicate degradation. Don't increase dose above 1mg. The issue is peptide quality or administration technique, not insufficient receptor activation.

This is receptor saturation spotting, caused by dosing too aggressively during the first 7–10 days before melanocyte activity equilibrates across all dermal regions. Reduce dose immediately to 0.5mg every other day and avoid UV exposure for 5–7 days. The uneven pigmentation will normalise over 3–4 weeks as melanin turnover homogenises the distribution. To prevent recurrence, never escalate dose faster than 0.5mg increments per week, and avoid injecting the same anatomical site repeatedly. Rotate injection sites across abdomen, thighs, and upper arms.

This indicates dosing above the photoprotective threshold. Melanocortin receptor activation is occurring systemically rather than being confined to UV-challenged melanocytes. Reduce maintenance doses by 25% (e.g., from 0.08mg/kg to 0.06mg/kg) and extend the dosing interval to every 72 hours instead of 48. Non-UV-exposed pigmentation provides no additional photoprotection and indicates the peptide is oversaturating receptors beyond what's needed for UV defense.

Skipping one maintenance dose (normally administered every 48–72 hours) reduces photoprotection by approximately 20–30% for the next 48 hours as MC1R signalling declines. If you realise the missed dose within 24 hours of the scheduled time, administer it immediately and resume the regular 48–72 hour schedule from that point. If more than 24 hours have passed, skip the missed dose entirely and dose on the next scheduled day. Do not double-dose to compensate, as this dramatically increases nausea risk without restoring photoprotection faster. During the 48-hour window after a missed dose, reduce UV exposure time by 30–40% or increase sunscreen SPF to compensate.

This is the recommended approach. Melanotan-1 increases baseline UV tolerance but does not replace broad-spectrum sunscreen. A 2× MED increase means skin that burns in 15 minutes can now tolerate 30 minutes, but prolonged exposure still causes DNA damage. Combining Melanotan-1 (which raises eumelanin density) with SPF 30+ sunscreen (which blocks UV photons before they reach the skin) provides layered photoprotection that neither intervention achieves alone. The peptide does not reduce sunscreen efficacy or vice versa.

No. Melanin has a biological half-life of approximately 30–40 days in the epidermis, so missing 7–10 days of maintenance dosing causes gradual fading rather than abrupt colour loss. Resume at your standard maintenance dose (0.5–1mg 2–3×/week); you don't need to re-enter loading phase unless pigmentation has faded more than 50% back toward baseline. If you've been off Melanotan-1 for more than six weeks, restart at half your previous loading dose to re-saturate melanocyte receptors safely.

This creates significant risk without evidence-based benefit. EPP diagnosis requires confirmatory erythrocyte protoporphyrin testing and genetic sequencing. Self-diagnosing based on sun sensitivity can miss other photosensitivity disorders (lupus, porphyria cutanea tarda, drug-induced photosensitivity) that require different management. Research-grade peptides lack the pharmacokinetic validation, sterility testing, and polymer matrix formulation that make afamelanotide implants effective and tolerable. Injecting non-validated peptides at arbitrary doses creates nausea, hyperpigmentation, and potential contamination risk without the controlled melanogenesis implants provide.

You'll get minimal photoprotection. Tyrosinase enzyme induction requires 96 hours of sustained MC1R activation, and starting only 48 hours before UV exposure means the melanocytes haven't upregulated melanin synthesis capacity yet. The best course of action is to proceed with the standard 0.16mg/kg dose daily but combine it with rigorous topical sunscreen use (SPF 30+ applied every two hours) and limit UV exposure to early morning or late afternoon when UVB intensity is below 50% of midday levels. Don't expect visible tanning until day four or five. The melanin is being synthesised but hasn't migrated to the epidermis yet.

Nausea typically peaks 24–72 hours post-implant as plasma afamelanotide rises and usually resolves within 4–7 days as CNS melanocortin receptors desensitise. Antiemetic medications (ondansetron 4–8mg as needed) are standard supportive care. If nausea persists beyond one week or causes vomiting that prevents oral intake, contact the prescribing dermatologist. This may indicate MC4R over-activation (a known off-target effect) that could warrant implant removal, though this is rare. Most patients tolerate subsequent implants better as their bodies adapt to sustained melanocortin signalling.

Increase to 1.5–2mg daily and add controlled UV exposure if you haven't already. 10–15 minutes of midday sun three times weekly. Some individuals are MC1R low-responders due to genetic variants in the melanocortin receptor gene, meaning their melanocytes require higher α-MSH concentrations to trigger tyrosinase upregulation. If pigmentation remains absent after 20 days at 2mg daily with UV pairing, you may carry a functionally null MC1R allele (common in red-haired, extremely fair-skinned populations), in which case Melanotan-1 will produce minimal cosmetic effect regardless of dose.

Reduce the next dose by 30–40% and split it into two smaller injections 12 hours apart. Nausea occurs when plasma alpha-MSH analog concentrations rise too quickly, activating melanocortin-4 receptors (MC4R) in the hypothalamus that regulate appetite and gastric motility. Slower titration allows receptor desensitization to occur gradually. Most individuals tolerate full loading doses by day 3–4 as MC4R downregulates in response to sustained agonist exposure.

Resume at the standard maintenance dose. Do not double-dose to 'catch up.' Missing 4–6 days of dosing reduces steady-state melanin levels by approximately 15–20%, but photoprotection remains above baseline. Administering a loading dose after a missed maintenance period causes unnecessary pigmentation spikes without improving UV defense. If more than 10 days have passed since the last dose, restart the loading phase at half the original dose (0.08mg/kg) for 5–7 days before returning to maintenance.